A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RESORCE
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 24 Oct 2017 Results of exploratory analysis assessing association between molecular biomarkers from tumor tissue and regorafenib clinical benefit presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 12 Sep 2017 Results of exploratory analysis assessing overall survival by using baseline platelet count from three studies (SHARP, AP, and RESORCE) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top